<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00918762</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000642940</org_study_id>
    <secondary_id>P30CA022453</secondary_id>
    <secondary_id>WSU-2008-022</secondary_id>
    <nct_id>NCT00918762</nct_id>
  </id_info>
  <brief_title>Transoral Robotic Surgery or Standard Surgery in Treating Patients With Benign or Malignant Tumors of the Larynx and Pharynx</brief_title>
  <official_title>A Pilot Study Assessing the Use of DA VINCI® Robotic Surgical System in Laryngeal and Pharyngeal Surgeries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Transoral robotic surgery may make it easier to find and remove benign or
      malignant tumors of the larynx and pharynx and cause less damage to normal tissue. It is not
      yet known whether transoral robotic surgery is more effective than standard surgery in
      diagnosing and treating larynx and pharynx tumors.

      PURPOSE: This phase I trial is studying how well transoral robotic surgery works compared
      with standard surgery in treating patients with benign or malignant tumors of the larynx or
      pharynx.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Evaluate the potential benefits of using the transoral robotic surgical approach against
           the conventional open and transoral approaches in patients with benign or malignant
           disease involving the larynx and pharynx.

      Secondary

        -  Determine the proportion of laryngeal and pharyngeal surgical procedures where the
           surgical exposure is adequate to allow the successful completion of the surgical
           resection using the transoral robotic surgical approach.

      OUTLINE: Patients are assigned to transoral robotic surgery or standard therapy consisting of
      conventional transoral endoscopic or open approach according to their preference.

      Patients undergo planned surgical procedures (either diagnostic or therapeutic) appropriate
      for their disease in the larynx or pharynx via the transoral robotic surgical approach or the
      conventional transoral endoscopic or open approach.

      Patients complete the Functional Assessment of Cancer Therapy Head and Neck Scale, the
      Performance Status Scale for Head and Neck Cancer Patients, and the University of Washington
      Quality of Life Scale at baseline and at 3 and 6 months. Patients also undergo voice analysis
      by acoustic analyses, and speech and swallow pathology evaluation by videostroboscopy and
      modified barium swallow.

      After completion of study procedure, patients are followed at 3 and 6 months.

      PROJECTED ACCRUAL: A total of 80 patients will be accrued to the control group (standard
      conventional surgery) and 30 patients will be accrued to the robotic surgery group.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Operative time that directly affects operative cost</measure>
    <time_frame>post operative</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood loss</measure>
    <time_frame>During surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra-operative and post-operative complications</measure>
    <time_frame>during the operation and post operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for reconstruction</measure>
    <time_frame>post operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Margins status</measure>
    <time_frame>post operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>during time as inpatient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tracheostomy and PEG dependence</measure>
    <time_frame>post operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days to oral intake</measure>
    <time_frame>post operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to locoregional recurrence</measure>
    <time_frame>post operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Speech intelligibility</measure>
    <time_frame>post operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>3 months and 6 month following completion of surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain</measure>
    <time_frame>post operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of robotic surgical cases where adequate surgical exposure allowed for successful operation completion</measure>
    <time_frame>post operative</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Head and Neck Cancer</condition>
  <condition>Perioperative/Postoperative Complications</condition>
  <condition>Precancerous Condition</condition>
  <arm_group>
    <arm_group_label>daVinci® Robotic Surgical System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will undergo a planned surgical procedures via the robotic approach.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>assessment of therapy complications</intervention_name>
    <arm_group_label>daVinci® Robotic Surgical System</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>diagnostic endoscopic surgery</intervention_name>
    <arm_group_label>daVinci® Robotic Surgical System</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <arm_group_label>daVinci® Robotic Surgical System</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <arm_group_label>daVinci® Robotic Surgical System</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic endoscopic surgery</intervention_name>
    <arm_group_label>daVinci® Robotic Surgical System</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>transoral robotic surgery</intervention_name>
    <arm_group_label>daVinci® Robotic Surgical System</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>video-assisted surgery</intervention_name>
    <arm_group_label>daVinci® Robotic Surgical System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Benign or malignant disease of the larynx or pharynx that requires surgical
             intervention for either diagnostic or therapeutic purposes

               -  Malignant disease must meet the following criteria:

                    -  Histologically confirmed diagnosis of 1 of the following:

                         -  Glottic cancer (T1, T2, and T3)

                         -  Supraglottic cancer (T1, T2, and T3)

                         -  Hypopharyngeal cancer (T1 and T2)

                         -  Oropharyngeal cancer (T1, T2, and T3)

                         -  Nasopharyngeal cancer (T1 and T2)

                    -  Resectable involved lymph nodes

                    -  No invasion of osseous and/or osseocartilaginous structures including the
                       following:

                         -  Mandibular bone

                         -  Thyroid cartilage

                         -  Hyoid bone

                         -  Cricoid bone

                         -  Vertebral body

                    -  No pharyngeal wall or tongue-based involvement requiring resection of &gt; 50%
                       of the posterior pharyngeal wall or tongue base

                    -  No radiological confirmation of carotid artery involvement

                    -  No fixation of tumor to the prevertebral fascia

                    -  No bilateral arytenoid involvement

                    -  No surgical defect requiring open approach for reconstruction

                    -  No evidence of distant metastasis

        PATIENT CHARACTERISTICS:

          -  Not pregnant

          -  No unexplained fever and/or untreated active infection

          -  No medical conditions contraindicating general anesthesia

          -  No inadequate jaw opening due to prior head and neck surgery, trauma, or radiotherapy

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ho-Sheng Lin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2009</study_first_submitted>
  <study_first_submitted_qc>June 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2009</study_first_posted>
  <last_update_submitted>May 7, 2014</last_update_submitted>
  <last_update_submitted_qc>May 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Barbara Ann Karmanos Cancer Institute</investigator_affiliation>
    <investigator_full_name>Ho-Sheng Lin</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>perioperative/postoperative complications</keyword>
  <keyword>precancerous condition</keyword>
  <keyword>stage I squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage II squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage I squamous cell carcinoma of the larynx</keyword>
  <keyword>stage I verrucous carcinoma of the larynx</keyword>
  <keyword>stage II squamous cell carcinoma of the larynx</keyword>
  <keyword>stage II verrucous carcinoma of the larynx</keyword>
  <keyword>stage III squamous cell carcinoma of the larynx</keyword>
  <keyword>stage III verrucous carcinoma of the larynx</keyword>
  <keyword>stage I lymphoepithelioma of the nasopharynx</keyword>
  <keyword>stage I squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage II lymphoepithelioma of the nasopharynx</keyword>
  <keyword>stage II squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage III lymphoepithelioma of the nasopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage I lymphoepithelioma of the oropharynx</keyword>
  <keyword>stage I squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage II lymphoepithelioma of the oropharynx</keyword>
  <keyword>stage II squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage III lymphoepithelioma of the oropharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the oropharynx</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Postoperative Complications</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

